PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
24269819-1	2013	Lonicerae flos extract (HS-23) is a clinical candidate currently undergoing Phase I trial in lipopolysaccharide (LPS)-injected healthy human volunteers, but its molecular basis remains to be defined.	hs-23	24-29	toll-like receptor 4	Mus musculus	113-116	
24269819-3	2013	Intravenous treatment with HS-23 rescued LPS-intoxicated C57BL/6J mice under septic conditions, and decreased the levels of cytokines such as tumor necrosis factor alpha (TNF-alpha), interleukin (IL)-1beta and high-mobility group box-1 (HMGB-1) in the blood.	hs-23	27-32	toll-like receptor 4	Mus musculus	41-44	
24269819-7	2013	HS-23 also inhibited various toll-like receptor agonists-induced nitric oxide (NO) production, and down-regulated LPS-induced expression of NF-kappaB/AP-1-target inflammatory genes in the cells.	hs-23	0-5	toll-like receptor 4	Mus musculus	114-117